Last edition
News about
Indian Pharmacopoeia Commission (IPC) hosts the Indian Pharmacopoeia (IP) 2026 Scientific Conclave and Interactive Session, focusing on medicine quality, impurity standards, regulatory science, and patient safety.
AstraZeneca Wins US FDA Approval for Fasenra in Hypereosinophilic Syndrome
AstraZeneca receives US Food and Drug Administration (FDA) approval for Fasenra to treat hypereosinophilic syndrome, supported by positive phase 3 NATRON trial results.
CuraTeQ Biologics Secures CDSCO Approval for Bevqolva
CuraTeQ Biologics receives CDSCO marketing authorisation for Bevqolva, strengthening its oncology biosimilars portfolio and expanding access to advanced cancer therapies.
Dr. Reddy's Launches Generic Semaglutide Injection in Canada
Dr. Reddy's Laboratories launches Canada’s first approved generic semaglutide injection after receiving Health Canada clearance, marking the first G7 market authorisation.
AstraZeneca's Imfinzi Combination Therapy Improves Survival Outcomes in Phase 3 Bladder Cancer Trial
AstraZeneca’s phase 3 VOLGA trial demonstrated significant survival benefits with Imfinzi and enfortumab vedotin in muscle-invasive bladder cancer patients who are ineligible for cisplatin-based chemotherapy, marking another positive milestone in the company’s immunotherapy programme.
Regenxbio Reports Positive Pivotal Trial Results for Duchenne Gene Therapy RGX-202
Regenxbio’s investigational gene therapy RGX-202 demonstrated strong microdystrophin expression, functional gains and a favourable safety profile in Duchenne muscular dystrophy patients, supporting plans for accelerated approval and a potential commercial launch in 2027.
VoxCell BioInnovation and adMare BioInnovations have launched a research partnership focused on validating antibody-based cancer therapies using advanced bioprinted human tissue models designed to improve predictive drug testing and accelerate oncology innovation.
Biogen Announces Topline Phase 2 Results for Diranersen in Early Alzheimer's Disease
Ionis partner Biogen announces topline phase 2 CELIA trial results for diranersen (BIIB080), showing reduced tau pathology and cognitive benefits in patients with early Alzheimer's Disease (AD).
Tempus AI Expands Strategic Partnership with Bristol Myers Squibb
Tempus AI expands its collaboration with Bristol Myers Squibb to use Artificial Intelligence (AI) and real-world data for optimising oncology and neuroscience clinical trials and improving regulatory success rates.
Alembic Pharmaceuticals Gets US FDA Tentative Nod for Darolutamide Tablets
Alembic Pharmaceuticals receives tentative US Food and Drug Administration (FDA) approval for Darolutamide Tablets 300 mg, a generic equivalent to Nubeqa by Bayer.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy